View in EDS HTML Full Text PDF Full Text

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.

Saved in:
Bibliographic Details
Title: Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Authors: Carneiro BA; Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.; Lifespan Cancer Institute, Providence, Rhode Island, USA., Papadopoulos KP; START San Antonio, San Antonio, Texas, USA., Strickler JH; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA., Lassman AB; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, the Herbert Irving Comprehensive Cancer Center, New York, New York, USA.; New York-Presbyterian Hospital, New York, New York, USA., Waqar SN; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA., Chae YK; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Patel JD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA., Shacham-Shmueli E; Department of Oncology, Sheba Medical Center, Ramat Gan, Israel., Kelly K; University of California Davis Comprehensive Cancer Center, Sacramento, California, USA., Khasraw M; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA., Bestvina CM; The University of Chicago Medicine, Chicago, Illinois, USA., Merrell R; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA., Huang K; AbbVie Inc., North Chicago, Illinois, USA., Atluri H; AbbVie Inc., North Chicago, Illinois, USA., Ansell P; AbbVie Inc., North Chicago, Illinois, USA., Li R; AbbVie Inc., North Chicago, Illinois, USA., Jin J; AbbVie Inc., North Chicago, Illinois, USA., Anderson MG; AbbVie Inc., North Chicago, Illinois, USA., Reilly EB; AbbVie Inc., North Chicago, Illinois, USA., Morrison-Thiele G; AbbVie Inc., North Chicago, Illinois, USA., Patel K; AbbVie Inc., North Chicago, Illinois, USA., Robinson RR; AbbVie Inc., South San Francisco, California, USA., Aristide MRN; AbbVie Inc., North Chicago, Illinois, USA., Gan HK; Medical Oncology Department, Austin Health, Heidelberg, VIC, Australia.
Source: Neuro-oncology advances [Neurooncol Adv] 2022 Dec 21; Vol. 5 (1), pp. vdac183. Date of Electronic Publication: 2022 Dec 21 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36814898
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Carneiro+BA%22">Carneiro BA</searchLink>; Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.; Lifespan Cancer Institute, Providence, Rhode Island, USA.<br /><searchLink fieldCode="AU" term="%22Papadopoulos+KP%22">Papadopoulos KP</searchLink>; START San Antonio, San Antonio, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Strickler+JH%22">Strickler JH</searchLink>; Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Lassman+AB%22">Lassman AB</searchLink>; Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, the Herbert Irving Comprehensive Cancer Center, New York, New York, USA.; New York-Presbyterian Hospital, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Waqar+SN%22">Waqar SN</searchLink>; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.<br /><searchLink fieldCode="AU" term="%22Chae+YK%22">Chae YK</searchLink>; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Patel+JD%22">Patel JD</searchLink>; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Shacham-Shmueli+E%22">Shacham-Shmueli E</searchLink>; Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.<br /><searchLink fieldCode="AU" term="%22Kelly+K%22">Kelly K</searchLink>; University of California Davis Comprehensive Cancer Center, Sacramento, California, USA.<br /><searchLink fieldCode="AU" term="%22Khasraw+M%22">Khasraw M</searchLink>; The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.<br /><searchLink fieldCode="AU" term="%22Bestvina+CM%22">Bestvina CM</searchLink>; The University of Chicago Medicine, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Merrell+R%22">Merrell R</searchLink>; Department of Neurology, NorthShore University Health System, Evanston, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Huang+K%22">Huang K</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Atluri+H%22">Atluri H</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Ansell+P%22">Ansell P</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Li+R%22">Li R</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+MG%22">Anderson MG</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Reilly+EB%22">Reilly EB</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Morrison-Thiele+G%22">Morrison-Thiele G</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Patel+K%22">Patel K</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Robinson+RR%22">Robinson RR</searchLink>; AbbVie Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Aristide+MRN%22">Aristide MRN</searchLink>; AbbVie Inc., North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Gan+HK%22">Gan HK</searchLink>; Medical Oncology Department, Austin Health, Heidelberg, VIC, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101755003%22">Neuro-oncology advances</searchLink> [Neurooncol Adv] 2022 Dec 21; Vol. 5 (1), pp. vdac183. <i>Date of Electronic Publication: </i>2022 Dec 21 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101755003 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2632-2498 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226322498%22">26322498 </searchLink><i>NLM ISO Abbreviation: </i>Neurooncol Adv <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36814898
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/noajnl/vdac183
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: vdac183
    Titles:
      – TitleFull: Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Carneiro BA
      – PersonEntity:
          Name:
            NameFull: Papadopoulos KP
      – PersonEntity:
          Name:
            NameFull: Strickler JH
      – PersonEntity:
          Name:
            NameFull: Lassman AB
      – PersonEntity:
          Name:
            NameFull: Waqar SN
      – PersonEntity:
          Name:
            NameFull: Chae YK
      – PersonEntity:
          Name:
            NameFull: Patel JD
      – PersonEntity:
          Name:
            NameFull: Shacham-Shmueli E
      – PersonEntity:
          Name:
            NameFull: Kelly K
      – PersonEntity:
          Name:
            NameFull: Khasraw M
      – PersonEntity:
          Name:
            NameFull: Bestvina CM
      – PersonEntity:
          Name:
            NameFull: Merrell R
      – PersonEntity:
          Name:
            NameFull: Huang K
      – PersonEntity:
          Name:
            NameFull: Atluri H
      – PersonEntity:
          Name:
            NameFull: Ansell P
      – PersonEntity:
          Name:
            NameFull: Li R
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Anderson MG
      – PersonEntity:
          Name:
            NameFull: Reilly EB
      – PersonEntity:
          Name:
            NameFull: Morrison-Thiele G
      – PersonEntity:
          Name:
            NameFull: Patel K
      – PersonEntity:
          Name:
            NameFull: Robinson RR
      – PersonEntity:
          Name:
            NameFull: Aristide MRN
      – PersonEntity:
          Name:
            NameFull: Gan HK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 12
              Text: 2022 Dec 21
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2632-2498
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Neuro-oncology advances
              Type: main
ResultId 1